3-methyl-6-[methyl-[(E)-phenethylideneamino]amino]-1H-pyrimidine-2,4-dione | 1448808-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-methyl-6-[methyl-[(E)-phenethylideneamino]amino]-1H-pyrimidine-2,4-dione
• 英文别名: 3-methyl-6-[methyl-[(E)-2-phenylethylideneamino]amino]-1Hpyrimidine-2,4-dione；3-methyl-6-[(2E)-1-methyl-2-(2-phenylethylidene)hydrazinyl]pyrimidine-2,4(1H,3H)-dione；3-methyl-6-[methyl-[(E)-2-phenylethylideneamino]amino]-1H-pyrimidine-2,4-dione
• CAS: 1448808-29-4
• 化学式: C₁₄H₁₆N₄O₂
• 分子量: 272.307
• InChiKey: GQAQZTHXSQAVRM-OQLLNIDSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-methyl-6-[methyl-[(E)-phenethylideneamino]amino]-1H-pyrimidine-2,4-dione 在 溶剂黄146 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 6.0h， 以38%的产率得到3-benzyl-1,6-dimethyl-pyrimido[5,4-e][1,2,4]triazine-5,7-dione
  参考文献：
  名称：

  新型KDM4C抑制剂的合理设计，合成和生物学分析。

  摘要：

  KDM4家族的人组蛋白脱甲基酶已经与诸如前列腺癌和乳腺癌的疾病有关。当前已知的大多数抑制剂都遭受酶同工型之间的低渗透性和低选择性。在这项研究中，毒素黄素被用于设计和合成具有改善的生物活性和体外ADME特性的新型KDM4C抑制剂。抑制剂表现出良好的被动细胞通透性和代谢稳定性。然而，减少氧化还原责任并因此对细胞生存力的非特异性影响仍然是一个挑战。

  DOI：

  10.1016/j.bmc.2019.115128
• 作为产物：
  描述：

  6-氯-3-甲基尿嘧啶 以 乙醇 为溶剂， 反应 0.34h， 生成 3-methyl-6-[methyl-[(E)-phenethylideneamino]amino]-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  新型KDM4C抑制剂的合理设计，合成和生物学分析。

  摘要：

  KDM4家族的人组蛋白脱甲基酶已经与诸如前列腺癌和乳腺癌的疾病有关。当前已知的大多数抑制剂都遭受酶同工型之间的低渗透性和低选择性。在这项研究中，毒素黄素被用于设计和合成具有改善的生物活性和体外ADME特性的新型KDM4C抑制剂。抑制剂表现出良好的被动细胞通透性和代谢稳定性。然而，减少氧化还原责任并因此对细胞生存力的非特异性影响仍然是一个挑战。

  DOI：

  10.1016/j.bmc.2019.115128

文献信息

• Toxoflavins and Deazaflavins as the First Reported Selective Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase II
  作者：Ali Raoof、Paul Depledge、Niall M. Hamilton、Nicola S. Hamilton、James R. Hitchin、Gemma V. Hopkins、Allan M. Jordan、Laura A. Maguire、Alison E. McGonagle、Daniel P. Mould、Mathew Rushbrooke、Helen F. Small、Kate M. Smith、Graeme J. Thomson、Fabrice Turlais、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1021/jm400568p

  日期：2013.8.22

  The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAP.) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.
• [EN] INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE<br/>[FR] INHIBITEURS DE CYSTATHIONINE BÊTA-SYNTHASE POUR RÉDUIRE LA SURPRODUCTION NEUROTOXIQUE DE SULFURE D'HYDROGÈNE ENDOGÈNE
  申请人：FOND JEROME LEJEUNE

  公开号：WO2010072807A2

  公开（公告）日：2010-07-01

  The invention is directed to inhibitors of cystathionine beta synthase which, among other biochemical effects, allow reduction of the neurotoxic overproduction of endogenous hydrogen sulphide. These compounds and pharmaceutical compositions containing them are useful for the prevention and treatment of neurotoxic and cognitive disorders such as cognitive disorders in Down syndrome. The invention also relates to methods for preventing or treating neurotoxic and cognitive disorders including cognitive disorders in Down Syndrome.
• Rational design, synthesis and biological profiling of new KDM4C inhibitors
  作者：Vatroslav Letfus、Dubravko Jelić、Ana Bokulić、Adriana Petrinić Grba、Sanja Koštrun

  DOI：10.1016/j.bmc.2019.115128

  日期：2020.1

  diseases such as prostate and breast cancer. Majority of currently known inhibitors suffer from the low permeability and low selectivity between the enzyme isoforms. In this study, toxoflavin motif was used to design and synthesize new KDM4C inhibitors with improved biological activity and in vitro ADME properties. Inhibitors displayed good passive cellular permeability and metabolic stability. However

  KDM4家族的人组蛋白脱甲基酶已经与诸如前列腺癌和乳腺癌的疾病有关。当前已知的大多数抑制剂都遭受酶同工型之间的低渗透性和低选择性。在这项研究中，毒素黄素被用于设计和合成具有改善的生物活性和体外ADME特性的新型KDM4C抑制剂。抑制剂表现出良好的被动细胞通透性和代谢稳定性。然而，减少氧化还原责任并因此对细胞生存力的非特异性影响仍然是一个挑战。